Navigation Links
Summary Letter to Hadasit Bio-Holdings Ltd. Shareholders
Date:10/26/2011

JERUSALEM, Oct. 26, 2011 /PRNewswire/ -- The following is a letter to shareholders from Ophir Shahaf, CEO of Hadasit Bio-Holdings, Ltd. (OTCBB: HADSY), a publicly traded portfolio of biotech companies based on intellectual property developed and owned by Hadassah University Hospital.

Dear Fellow Investors,

Hadasit Bio-Holdings is celebrating six years since its establishment by the Hadassah University Hospital and its IPO which made public participation in leading biotechnological developments, based on the scientific and medical knowledge and experience of the Hadassah institution, possible.

Over the years, many emerging companies have turned to public markets for financing and the general public has been more exposed to the world of biotechnology and medical developments as a result.  During this time, we have had strong business and clinical progress in our portfolio and the value of our subsidiary companies has grown significantly. That said, the economy and overall market have provided its fair share of challenges.

Similar to 2008, we are witnessing the upheavals occurring in the global economy which are impacting the financial markets in particular.  Despite economic conditions, the standard of medical treatment around the world continues to improve. As such, world life expectancy is on the rise, resulting in a rise in disease. In light of these trends, pharmaceutical companies are continuing their research efforts, and capital investments are driving the improvement of existing developments as well as propelling the introduction of new ones.  Hadasit Bio-Holdings is taking part in this effort as well while enjoying its strong market position – a point worth making as the scientific base and the developmental abilities of Hadasit's portfolio companies have remained strong. Hadassah is world-renown in the fields of Oncology, Tissue Engineering, Autoimmune Diseases and continues to be a leading center of medic
'/>"/>

SOURCE Hadasit Bio-Holdings Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xian Qinba Xintong Medical Ltd.
2. CTI Receives NASDAQ Letter
3. Synvista Therapeutics Posts Letter to Stockholders on Web Site
4. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
5. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
6. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
7. Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
8. Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter
9. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
10. Caraco Pharmaceutical Laboratories, Ltd. Receives FDA Warning Letter
11. deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... December 16, 2014 “Never say, ... Philipps- Universität Marburg’s Department of Physics, advises young ... the newly released SPIE Women in Optics ... too shy to ask questions.” , In the ... and mathematics) occupations ranging from university professor and ...
(Date:12/17/2014)... December 17, 2014 Xeno Diagnostics ... following its most recent COLA inspection. Xeno has ... a national healthcare accreditation organization. Accreditation is earned ... quality in day-to-day operations, demonstrate continued accuracy in ... rigorous on-site laboratory survey. , While ...
(Date:12/17/2014)... Md. , Dec. 17, 2014 CASI ... company dedicated to the acquisition, development and commercialization of ... for the global market with a primary commercial focus ... it has been granted a Type C meeting with ... the meeting will be held in February 2015.  During ...
(Date:12/15/2014)... DIEGO , Dec. 15, 2014 ... three-dimensional biology company focused on delivering breakthrough 3D ... the industry and collaborators of its exVive3D TM ... made widely available in full commercial release on ... the field, resulting in several awards for innovation. ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3
... Chilcott,Limited (Nasdaq: WCRX ) announced today that LEO ... from the U.S. Patent and,Trademark Office (the "USPTO"). In ... Patent No. 6,753,013 (the "013 Patent") in,response to a ... TACLONEX,and certain of LEO,s products in development. Warner Chilcott ...
... 17 Diageo (NYSE: DEO ),the world,s leading ... sponsorship of a physician,s training program in screening and ... State of,New York (MSSNY). The program, funded entirely ... better prepare physicians to address and assess issues,related to ...
... LMNX ) today announced that management will present ... held September,17-20, 2007, at the St. Regis Hotel in ... Balthrop, president and chief,executive officer, will begin at 11:00 ... 18, 2007. The presentation will be webcast live,and may ...
Cached Biology Technology:Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent 2Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent 3Diageo Sponsors Medical Society of the State of New York's Physicians Training Program 2Diageo Sponsors Medical Society of the State of New York's Physicians Training Program 3Luminex Corporation to Present at ThinkEquity Partners Investor Conference 2
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a ... announced that its DigitalPersona ® Pro Enterprise ... have been deployed throughout First Bank branch locations ... South Carolina and Virginia. First Bank, ... Southern Pines, North Carolina , selected ...
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... (BMC) and Boston University School of Public Health (BUSPH) ... at home are less likely to receive colorectal cancer ... English at home. The findings, which currently appear on-line ... patient-provider language barriers play a role in health-care disparities, ...
... to Secretary Kathleen Sebelius at the U.S. Department of ... called out 10 specific challenges to proposed modifications to ... on behalf of its membership of 4,000 informatics professionals, ... of Proposed Rulemaking (NPRM) on HIPAA modifications, along with ...
... frigatebird may be the least likely animal on the ... turns out the Galapagos population of this tropical seabird ... new conservation status, according to a paper by researchers ... Museum of Natural History and the University of Missouri-St. ...
Cached Biology News:Study finds language barriers may play role in health care disparities 2AMIA cites concerns about proposed HIPAA modifications 2AMIA cites concerns about proposed HIPAA modifications 3AMIA cites concerns about proposed HIPAA modifications 4Smithsonian researchers find differences between Galapagos and mainland frigatebirds 2
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap. (2/sp, 20/ca) Packaging: 2 / pack, 20 /...
... Display Vector is specifically designed to target ... of Saccharomyces cerevisiae. Displayed proteins can be ... known or putative ligands. pYD1 uses the ... two domains, Aga1 and Aga2, to display ...
... are used for heterologous protein expression in the ... S2 cell line was derived from a primary ... Drosophila melanogaster embryos (1). This versatile ... CO2 and is easily adapted to suspension culture. ...
ACS Reagent Grade C 19 H 14 O 5 S Formula Weight: 354.38 PRODUCT SPECIFICATIONS Form: Rust/red crystalline powder Clarity of Solution: Passes test Visual Transition Interval: pH 6.8 - Yellow pH 8.2...
Biology Products: